Inhalation Drug Delivery News

  1. Intravacc Announces Additional Favorable Preclinical And Toxicology Data For Avacc 10®, An Intranasal SARS-CoV-2 Candidate Vaccine 9/12/2022

    Intravacc, a world leader in translational research and development of preventive and therapeutic vaccines, today announced additional favorable preclinical and toxicology data for Avacc 10®, the company's SARS-CoV-2 intranasal candidate vaccine

  2. Hovione Expands Drug Product Offering With A New Manufacturing Line Dedicated To Continuous Tableting 9/6/2022

    Hovione, the leader in spray drying and particle engineering, announced today that it has expanded its continuous manufacturing offering and services. A new state-of-the-art continuous manufacturing facility is now coming online at the Loures site in Portugal

  3. CDMO Hovione Expands With New Manufacturing Line For Continuous Tableting Operations 9/6/2022

    Hovione, the leader in spray drying and particle engineering, announced today that it has expanded its continuous manufacturing offering and services. A new state-of-the-art continuous manufacturing facility is now coming online at the Loures site in Portugal.

  4. Zerion Pharma And Insud Pharma Announce Collaboration To Develop Dispersome Formulations Of Marketed Drug Products 8/29/2022

    The Danish pharmaceutical company Zerion Pharma A/S (ZERION) and the Spanish pharmaceutical group Insud Pharma, SL today are announcing their collaboration to develop and commercialize drug products applying ZERION’s solubility enhancing Dispersome technology

  5. Zerion Pharma And Hovione Extend Partnership To Cover Use Of The Dispersome® Technology Platform In Nutraceuticals 8/23/2022

    Hovione and Zerion Pharma A/S (Zerion) today announced an extension of their collaboration on Zerion's Dispersome® technology into the nutraceutical/dietary supplements field

  6. Piramal Pharma Solutions Holds Grand Opening Ceremony For New API Plant At Aurora, Canada Manufacturing Site 7/12/2022

    Piramal Pharma Limited's Pharma Solutions business, a leading Contract Development and Manufacturing Organization (CDMO), held a Grand Opening to celebrate the official inauguration of a new active pharmaceutical ingredient (API) plant at the company's site in Aurora, Ontario.

  7. Naobios Delivers FluGen Inc's M2SR Influenza Vaccine Candidate For Upcoming Clinical Trials 6/21/2022

    Naobios, a CDMO (Contract Development and Manufacturing Organization) providing bioprocess development and GMP production of clinical batches of viral vaccines BSL2/BSL3, oncolytic viruses and viral vectors, today announces it has successfully completed the development and GMP manufacturing of the clinical batch of M2SR influenza vaccine-candidate for FluGen, Inc., a clinical-stage vaccine company transforming vaccine efficacy in infectious respiratory diseases

  8. Lonza Completes Dedicated Early Clinical Phase Development And Manufacturing Facility In Bend (OR) 6/1/2022

    Lonza has enhanced its offering for customers in the early phases of their clinical trials by adding a dedicated Early Phase Clinical Manufacturing facility at its Small Molecules site in Bend, Oregon.

  9. Piramal Pharma Solutions New API Plant In Canada Goes Online; Initial Production Runs Successfully Completed 5/19/2022

    Piramal Pharma Limited's Pharma Solutions business, a leading Contract Development and Manufacturing Organization (CDMO), today announced that a new active pharmaceutical ingredient (API) plant at the company's site in Aurora, Ontario, has come online and successfully completed its initial production runs

  10. Rokote Laboratories Selects Exothera For GMP Manufacturing Of Its Second-Generation Coronavirus Vaccine FINCoVac 2.0. 3/31/2022

    Rokote Laboratories Finland Ltd., a vaccine development company focussing on a second-generation COVID-19 vaccine, and Exothera S.A. will collaborate to bring the intranasal coronavirus vaccine FINCoVac 2.0 to clinical Phase I/II trials